Schedule M Pharmaceutical Manufacturing refers to the Good Manufacturing Practices (GMP) and requirements for premises, plant, and equipment that pharmaceutical manufacturers in India must follow under the Drugs Rules, 1945.
The revised Schedule M notified through G.S.R. 922(E) on 28 December 2023 significantly expanded the framework. It introduced a stronger focus on the Pharmaceutical Quality System (PQS), Quality Risk Management (QRM), documented procedures, validation, qualification, Product Quality Review (PQR), and other modern GMP controls.
For manufacturers, Schedule M is not simply a certificate or a one-time factory inspection. It affects how a pharmaceutical plant designs its facility, controls materials, manages production, performs testing, documents activities, handles deviations, trains employees, and maintains product quality.
Important 2026 update: CDSCO’s official notifications show that the revised Schedule M was notified in December 2023 and that extensions were subsequently provided for eligible small and medium manufacturers. The extension for eligible manufacturers with turnover of ₹250 crore or less ran through 31 December 2025. Therefore, manufacturers should not assume that the old transition period continues in 2026.
Regulatory note: This article explains Schedule M from an educational and compliance-planning perspective. Manufacturers should verify the latest notification, licence conditions, applicable State Drug Control requirements, and product-specific regulatory requirements before making compliance decisions.
Schedule M Pharmaceutical Manufacturing: Requirements & GMP Guide
Schedule M Pharmaceutical Manufacturing means manufacturing pharmaceutical products according to the Good Manufacturing Practices and requirements for premises, plant and equipment prescribed under Schedule M of the Drugs Rules, 1945.
The revised framework places strong emphasis on pharmaceutical quality systems, quality risk management, documented procedures, trained personnel, suitable facilities, qualified equipment, validation, testing, sanitation, data integrity, and continuous quality improvement. The revised Schedule M was notified by the Ministry of Health and Family Welfare through G.S.R. 922(E) on 28 December 2023.
In practical terms, Schedule M helps ensure that medicines are consistently manufactured and controlled according to defined quality and safety requirements.
What Is Schedule M in Pharmaceutical Manufacturing?
Schedule M forms part of India’s Drugs Rules, 1945 and establishes GMP and facility-related requirements for pharmaceutical products.
The official Schedule M title is:
“Good Manufacturing Practices and Requirements of Premises, Plant and Equipment for Pharmaceutical Products.”
It applies to pharmaceutical manufacturing operations covered by the relevant drug manufacturing licensing framework. The objective goes beyond producing a medicine according to a formula. A compliant manufacturer must build a system that controls the entire manufacturing process.
This includes:
- Raw-material control
- Supplier qualification
- Receipt and storage
- Sampling and testing
- Production
- In-process controls
- Packaging
- Labelling
- Quality control
- Quality assurance
- Equipment qualification
- Process validation
- Cleaning and sanitation
- Documentation
- Batch release
- Complaints
- Product recalls
- Self-inspection
- Personnel training
- Quality risk management
The revised framework also makes senior management responsible for ensuring that an effective pharmaceutical quality system exists and receives adequate resources.
Why Is Schedule M Important for Pharmaceutical Manufacturers?
A pharmaceutical manufacturing plant cannot depend only on the final laboratory test to demonstrate product quality. Quality must be built into the manufacturing process.
For example, if a tablet manufacturer receives an incorrect API, uses an inadequately cleaned blender, records an incorrect processing time, or fails to control environmental conditions, the final product may not meet its intended quality.Schedule M addresses these risks through a structured GMP system.
Major objectives include:
- Consistent product quality
- Patient safety
- Controlled manufacturing processes
- Prevention of contamination
- Prevention of mix-ups
- Reliable documentation
- Traceability
- Effective quality control
- Risk-based decision-making
- Continuous improvement
This is why Schedule M compliance for pharmaceutical manufacturers should be treated as an integrated quality-management programme rather than a paperwork exercise.
Revised Schedule M: What Changed?
The revised Schedule M notified in 2023 modernised India’s GMP framework. The official notification changed the description of Schedule M to include not only GMP but also requirements for premises, plant and equipment for pharmaceutical products.
Some important areas include:
|
Area |
Compliance Focus |
|
Pharmaceutical Quality System |
Integrated quality management |
|
Quality Risk Management |
Identification and control of quality risks |
|
Personnel |
Qualified and trained staff |
|
Premises |
Suitable layout and controlled environment |
|
Equipment |
Qualification, maintenance and calibration |
|
Documentation |
Controlled and traceable records |
|
Production |
Defined and controlled processes |
|
Quality Control |
Sampling, testing and release |
|
Validation |
Demonstrated process and system performance |
|
Product Quality Review |
Periodic assessment of product quality |
|
Complaints |
Investigation and corrective action |
|
Recalls |
Effective product-recall systems |
|
Self-inspection |
Internal compliance monitoring |
|
Data integrity |
Reliable and controlled records |
Schedule M GMP Requirements
The Schedule M GMP requirements cover multiple interconnected areas.
1. Pharmaceutical Quality System
The revised framework places significant importance on the Pharmaceutical Quality System.
A good PQS should connect:
- Quality Assurance
- Quality Control
- Production
- Engineering
- Warehouse
- Regulatory functions
- Supply chain
- Qualified suppliers
- Senior management
The manufacturer should clearly define responsibilities and authorities.
The official Schedule M notification issued by the Central Drugs Standard Control Organisation (CDSCO) states that the quality objective requires an appropriately designed pharmaceutical quality system incorporating GMP and Quality Risk Management
2. Quality Risk Management
Quality Risk Management helps manufacturers identify potential risks before they become quality failures.
A practical QRM programme may evaluate:
- Cross-contamination
- Mix-ups
- Raw-material variability
- Equipment failure
- Process deviations
- Environmental risks
- Supplier risks
- Data-integrity risks
- Packaging errors
Manufacturers should document the risk assessment and establish appropriate controls.
Schedule M Infrastructure Requirements
The physical plant plays an important role in Schedule M compliance.
A pharmaceutical facility should have an appropriate layout that supports controlled movement of:
- Personnel
- Raw materials
- Packaging materials
- Equipment
- Finished products
- Waste
The layout should reduce the risk of:
- Contamination
- Cross-contamination
- Mix-ups
- Uncontrolled movement
- Incorrect material identification
Important facility considerations
Depending on the dosage form and manufacturing activity, manufacturers should assess:
- Manufacturing areas
- Warehousing areas
- Sampling areas
- Dispensing areas
- Packaging areas
- Quality-control laboratories
- Utilities
- Personnel facilities
- Cleaning facilities
- Waste-management arrangements
- Controlled storage conditions
The exact infrastructure requirement depends on the products and processes manufactured at the site.
Schedule M Facility Requirements
A compliant pharmaceutical facility should provide suitable environmental and operational controls.
Important considerations include:
Building design
The building should support:
- Easy cleaning
- Proper maintenance
- Controlled movement
- Prevention of contamination
- Suitable production flow
Storage areas
Warehouses should provide appropriate segregation and identification for materials such as:
- Approved materials
- Quarantined materials
- Rejected materials
- Returned goods
- Recalled products
- Finished products
Production areas
Production rooms should suit the manufacturing operation and should allow appropriate cleaning, maintenance and process control.
Laboratory areas
Quality-control laboratories should have suitable facilities and equipment for the testing activities they perform.
Schedule M Equipment Requirements
Equipment is a major component of Schedule M manufacturing standards.
Manufacturers should establish systems for:
- Equipment selection
- Installation
- Qualification
- Calibration
- Preventive maintenance
- Cleaning
- Operation
- Breakdown management
- Change control
- Retirement or replacement
Equipment should be suitable for its intended use.
For example, a tablet manufacturing plant may require controlled and qualified equipment for:
- Dispensing
- Sifting
- Granulation
- Blending
- Compression
- Coating
- Inspection
- Packaging
The specific equipment depends on the dosage form and process.
Schedule M Production Requirements
Production must follow approved procedures and manufacturing instructions.
A controlled production system should address:
- Material identification
- Line clearance
- Equipment status
- Batch documentation
- Weighing and dispensing
- Manufacturing stages
- In-process controls
- Yield reconciliation
- Packaging
- Labelling
- Finished-product transfer
Operators should record activities at the time they occur. A common compliance weakness is incomplete or retrospective documentation. Manufacturers should design systems that make accurate recording practical.
Schedule M Quality Control Requirements
Quality Control is responsible for testing and evaluating materials and products according to approved specifications and procedures.
Depending on the product, testing may cover:
- Identity
- Assay
- Related substances
- Dissolution
- Disintegration
- Microbial quality
- Physical characteristics
- Stability-related parameters
The laboratory should maintain appropriate:
- Specifications
- Test methods
- Reference standards
- Instruments
- Calibration records
- Test records
- Laboratory investigations
- Results
- Controlled procedures
Quality Control should work independently enough to provide objective testing and release decisions within the manufacturer’s quality system.
Schedule M Quality Assurance Requirements
Quality Assurance provides the broader system that ensures manufacturing and testing activities remain controlled. A reliable allopathic medicine manufacturing company should have effective systems for deviation management, CAPA, change control, training, validation oversight, and document control.
Important QA activities can include:
- SOP approval
- Batch-record review
- Deviation management
- CAPA
- Change control
- Internal audits
- Supplier qualification
- Training
- Validation oversight
- Document control
- Complaint investigation
- Recall coordination
- Product Quality Review
A strong QA system does not simply identify mistakes after they happen. It aims to prevent recurring problems.
Schedule M Documentation Requirements
One of the most important parts of Schedule M documentation requirements is traceability.
A manufacturer should be able to answer questions such as:
- Which raw-material batch was used?
- Which finished batch used that material?
- Who performed the operation?
- Which equipment was used?
- Was the equipment clean and qualified?
- Which test method was used?
- Who reviewed the result?
- Were there deviations?
- What CAPA did the company implement?
- Where did the finished batch go?
Typical controlled documents and records may include:
Quality documents
- Quality manual
- Quality policies
- Quality risk assessments
- Quality agreements
- SOPs
- Specifications
- Master documents
Production records
- Batch manufacturing records
- Batch packaging records
- Equipment-use records
- Cleaning records
- In-process control records
Laboratory records
- Test procedures
- Analytical records
- Instrument records
- Calibration records
- Reference-standard records
- Stability records
Quality-system records
- Deviations
- CAPA
- Change controls
- Complaints
- Recalls
- Training records
- Audit reports
- Supplier qualification records
Services Offered:
- Social Media Marketing/Creation of Content.
- Branding & Graphic Design
- Website Design & UI/UX, Video Marketing & Animation, Strategy and Implementation of Campaigns.
- Influencer Marketing
Reasons to Use Communication Crafts:
- Good creative skills in brand and visual identity.
- Demonstrated capability to drive up the engagement.
- Hands-on in social media strategy in lifestyle and retail brands.
Schedule M Validation Requirements
Validation provides documented evidence that a process, system, method or equipment performs consistently as intended.
Depending on the manufacturing operation, validation activities may include:
- Process validation
- Cleaning validation
- Analytical method validation
- Computerised-system validation
- Utility qualification
- Equipment qualification
- HVAC-related qualification
- Water-system qualification
Qualification and validation should follow a planned approach rather than occur only when an inspection approaches.
Schedule M Sanitation Requirements
Good sanitation reduces contamination risks.
Manufacturers should establish documented procedures for:
- Cleaning
- Disinfection
- Personnel hygiene
- Equipment cleaning
- Area cleaning
- Waste handling
- Pest control
- Cleaning verification
- Cleaning validation where applicable
Cleaning procedures should clearly define responsibilities, frequency, methods and acceptance criteria where appropriate.
Personnel Requirements Under Schedule M
People are one of the most important parts of pharmaceutical GMP.
A facility needs appropriately qualified personnel for functions such as:
- Production
- Quality Assurance
- Quality Control
- Engineering
- Warehouse
- Regulatory operations
Employees should receive training relevant to their responsibilities.
Training should cover areas such as:
- GMP
- Hygiene
- SOPs
- Data integrity
- Safety
- Contamination control
- Job-specific procedures
Training effectiveness should also be assessed where appropriate.
Schedule M Audit Requirements
Internal audits and self-inspection help identify weaknesses before regulatory inspections expose them.
A practical audit programme should review:
- Premises
- Equipment
- Documentation
- Production
- Laboratory
- Warehouse
- Personnel
- Validation
- Cleaning
- Calibration
- Data integrity
- Complaints
- CAPA
- Supplier controls
What should happen after an audit?
A useful audit process is:
Finding → Root Cause → CAPA → Implementation → Effectiveness Check
Simply closing an observation on paper does not prove that the underlying problem has been solved.
Schedule M Compliance Checklist
Use this as a high-level starting checklist.
Facility
- Suitable manufacturing layout
- Appropriate material and personnel movement
- Suitable storage areas
- Controlled production areas
- Adequate utilities
- Appropriate sanitation arrangements
Equipment
- Equipment qualification
- Calibration programme
- Preventive maintenance
- Cleaning procedures
- Equipment identification
- Equipment-use records
Quality
- Pharmaceutical Quality System
- Quality Risk Management
- Quality Assurance system
- Quality Control system
- Deviation management
- CAPA
- Change control
Production
- Approved master documents
- Batch manufacturing records
- Line clearance
- In-process controls
- Yield reconciliation
- Packaging controls
Documentation
- SOP system
- Document control
- Training records
- Batch records
- Laboratory records
- Calibration records
- Validation documents
Regulatory readiness
- Valid manufacturing licence
- Applicable product permissions
- Required technical staff
- Inspection readiness
- Corrective-action system
This checklist provides a starting point. It should not replace a product- and facility-specific regulatory gap assessment.
Schedule M Certification Requirements: Is There a “Schedule M Certificate”?
This point often creates confusion. Schedule M is primarily a regulatory GMP framework and set of manufacturing requirements; it should not be treated simply as a standalone commercial certificate.
Manufacturers may hold or pursue different certificates or regulatory documents depending on the applicable licensing and certification framework.
For example, businesses may encounter:
- GMP-related certification
- WHO-GMP certification
- Manufacturing licences
- Certificates of Pharmaceutical Product
- Product approvals
- Other regulatory permissions
The exact requirement depends on the manufacturing activity, product category, licence and applicable authority.
Therefore, a company claiming “Schedule M certified” should be asked to explain which regulatory document it holds, which authority issued it, what site it covers, and what products or dosage forms it covers.
Schedule M vs WHO-GMP
These terms are related but should not be treated as identical.
Factor | Schedule M | WHO-GMP |
Indian regulatory framework | Yes | May support international GMP expectations |
Focus | GMP plus premises, plant and equipment | GMP principles and quality systems |
Indian drug manufacturing compliance | Central requirement where applicable | Can provide additional regulatory/commercial value |
Quality systems | Required | Required |
Facility controls | Required | Required |
International positioning | Depends on additional approvals/certifications | Often useful for international markets |
Equivalent in every situation? | No | No |
The revised Indian Schedule M contains modern quality-system concepts, but manufacturers should not automatically describe Schedule M compliance as equivalent to every WHO-GMP or foreign regulatory requirement.
Schedule M Compliance Benefits
Proper compliance can provide several practical benefits.
1. Better product consistency
Controlled processes reduce unwanted variation between batches.
2. Lower contamination risk
Facility, cleaning and process controls help reduce contamination and mix-up risks.
3. Better inspection readiness
A functioning quality system makes regulatory inspections easier to manage.
4. Improved traceability
Good records allow manufacturers to trace materials, production activities and finished batches.
5. Stronger customer confidence
Distributors, institutional buyers and business partners often prefer manufacturers with strong quality systems.
6. Better international readiness
A mature GMP system can provide a stronger foundation for additional regulatory requirements in export markets.
7. Reduced recurring deviations
Root-cause analysis and CAPA can prevent the same quality problem from repeatedly occurring.
Common Schedule M Compliance Gaps
In real manufacturing environments, compliance problems often arise from implementation rather than from a lack of written SOPs.
Common gaps may include:
1. SOPs exist but employees do not follow them
A document alone does not create compliance.
2. Training is incomplete
Employees need practical understanding, not only attendance certificates.
3. Poor documentation practices
Missing signatures, overwritten entries and unexplained corrections can create serious data-integrity concerns.
4. Weak CAPA
A company may correct the immediate problem without addressing its root cause.
5. Inadequate change control
Facility, equipment, materials or process changes should receive appropriate evaluation before implementation.
6. Validation gaps
Some manufacturers treat validation as a one-time project instead of maintaining a lifecycle approach.
7. Supplier controls are weak
Raw-material quality can directly affect finished-product quality.
8. Internal audits are superficial
A useful audit should identify real risks rather than simply confirm that documents exist.
How to Prepare a Pharmaceutical Factory for Schedule M Compliance
A practical implementation approach can follow these stages.
Step 1: Conduct a gap assessment
Compare the existing facility and quality system against the applicable revised Schedule M requirements.
Step 2: Classify the gaps
Separate findings into:
- Critical
- Major
- Minor
- Documentation
- Infrastructure
- Equipment
- Personnel
- Quality-system gaps
Step 3: Create an upgrade plan
Give each gap:
- Responsible person
- Target date
- Required resources
- Risk level
- Verification method
Step 4: Upgrade the facility
Address physical deficiencies before relying only on documentation.
Step 5: Qualify equipment and utilities
Ensure critical systems have appropriate qualification and supporting records.
Step 6: Strengthen the PQS
Implement or improve:
- QRM
- CAPA
- Change control
- Deviation management
- Document control
- Training
- Internal audits
Step 7: Train employees
Make training practical and role-specific.
Step 8: Perform an internal audit
Audit the plant as if an external inspector were arriving.
Step 9: Close gaps
Verify that CAPA actually works.
Step 10: Maintain continuous compliance
Schedule M compliance should become part of routine operations rather than a project completed only before inspection.
Expert Tips for Schedule M GMP Compliance
Tip 1: Do not start with paperwork
Start with a risk-based gap assessment.
If your facility has a major infrastructure problem, writing another SOP will not solve it.
Tip 2: Link QA with production
Quality cannot operate as an isolated department.
Production, engineering, warehouse and QC must work within the same quality system.
Tip 3: Keep records inspection-ready
A good rule is:
If an activity is important to product quality, the manufacturer should be able to demonstrate what happened, when it happened, who performed it and who reviewed it.
Tip 4: Treat CAPA seriously
Do not use “operator training” as the automatic root cause for every deviation.
Ask why the system allowed the error to occur.
Tip 5: Review suppliers
A reliable supplier-control programme can prevent many quality problems before materials enter production.
Tip 6: Do not confuse certificates with compliance
A certificate displayed on a wall does not replace day-to-day GMP implementation.
Tip 7: Keep regulatory information current
Schedule M requirements and related drug regulations can change through government notifications. CDSCO maintains official pages for the Drugs Rules and Gazette Notifications, so manufacturers should check current regulatory documents rather than rely on old blog posts.
Schedule M and Pharmaceutical Manufacturing in India
India’s pharmaceutical manufacturing sector includes:
- Large manufacturers
- Medium-sized manufacturers
- Small manufacturers
- Contract manufacturers
- Third-party manufacturers
- Export-oriented facilities
- API manufacturers
- Formulation manufacturers
The compliance burden can differ depending on the manufacturing activity, dosage form, facility and applicable licence.For example, a tablet facility and a sterile injectable facility cannot use the same facility-control strategy.
Sterile manufacturing requires much stronger contamination-control measures, environmental controls and process controls than many non-sterile operations.Therefore, Schedule M requirements in India should always be interpreted in the context of the actual manufacturing operation.
Does Schedule M Apply to Third-Party Pharmaceutical Manufacturing?
Yes, the regulatory responsibility does not disappear simply because a company uses a contract or third-party manufacturer.
A marketing company should carefully evaluate its manufacturing partner’s:
- Manufacturing licence
- GMP status
- Facility
- Quality system
- Product capabilities
- Testing arrangements
- Batch documentation
- Stability programme
- Complaint handling
- Recall procedures
- Regulatory history
A third-party manufacturing agreement should clearly define responsibilities between the parties.
Schedule M and PCD Pharma Businesses
PCD pharma companies generally do not manufacture medicines simply because they hold a franchise or distribution business.
However, if a PCD company works with a manufacturer for private-label or third-party production, the manufacturing facility becomes an important part of supplier evaluation.
Before placing a large order, evaluate:
- Manufacturing licence
- Applicable GMP documentation
- Product approvals
- Batch testing
- Manufacturing capability
- MOQ
- Packaging controls
- Stability information
- Delivery reliability
- Complaint handling
This can help distributors and pharma franchise businesses choose manufacturers based on quality rather than price alone.
Market Demand and Business Importance
Schedule M compliance is not a pharmaceutical “market product” in itself. Its business importance comes from the increasing need for reliable, compliant manufacturing systems.
For pharmaceutical companies, strong GMP implementation can support:
- Domestic manufacturing
- Institutional supply
- Contract manufacturing
- Private-label manufacturing
- Export opportunities
- Customer confidence
- Regulatory readiness
The commercial value comes from building a dependable manufacturing operation, not from simply using the phrase “Schedule M compliant” in marketing material.
Conclusion
Schedule M Pharmaceutical Manufacturing is fundamentally about building a controlled pharmaceutical manufacturing system rather than collecting a certificate.
The revised framework has strengthened India’s GMP expectations by placing greater emphasis on the Pharmaceutical Quality System, Quality Risk Management, documented processes, validation, quality control, facility controls and continuous improvement.
For manufacturers, the most effective approach is to combine facility upgrades, qualified equipment, trained personnel, strong documentation, effective QA/QC systems, risk management and continuous monitoring.
Most importantly, manufacturers should use the latest official CDSCO and Ministry of Health notifications when making compliance decisions because regulatory timelines and requirements can change.
Schedule M Pharmaceutical Manufacturing - FAQs
What is Schedule M Pharmaceutical Manufacturing?
What is the purpose of Schedule M?
When was the revised Schedule M notified?
What are the major revised Schedule M requirements?
Is Schedule M the same as WHO-GMP?
ABOUT THE AUTHOR
Mitesh Vyas
My name is Mitesh Vyas, and I am a Pharma Franchise Consultant and Industry Research Analyst specializing in India’s PCD pharma business ecosystem. My work focuses on helping beginners, distributors, and small pharma entrepreneurs understand the real-world functioning of the pharma franchise model. Unlike theoretical content, my insights are based on ground-level observations from Indian pharmaceutical markets, including Tier-1, Tier-2, and Tier-3 cities such as Ahmedabad, Indore, Lucknow, and surrounding business hubs. I regularly share insights on how the pharma franchise business in India works in real market conditions, including investment, product strategy, and growth challenges.
